Uma Borate: Evaluating MBG453 in High-Risk MDS and AML

preview_player
Показать описание
Combining MBG453 with hypomethylating agents was "extremely well tolerated," with no high-grade immune-related toxicities. Uma Borate, MD, discusses the safety and preliminary efficacy data.
  1. American Society of Hematology
  2. 2019 ASH Annual Meeting
Рекомендации по теме
Uma Borate: Evaluating 0:04:32

Uma Borate: Evaluating MBG453 in High-Risk MDS and AML

Meet Uma Borate, 0:02:28

Meet Uma Borate, MD, MSc, Hematologist at the OSUCCC – James

MBG453 with hypomethylating 0:07:28

MBG453 with hypomethylating agents in AML and high-risk MDS

Podcast: How genetic 0:31:38

Podcast: How genetic testing improves blood cancer detection | OSUCCC – James

Uma Borate | 0:04:34

Uma Borate | ASCO 2018 | Impact of targeted therapy on treatment of AML

Evaluating the Magrolimab-Based 0:04:19

Evaluating the Magrolimab-Based Triplet Combination in High-Risk AML

Anti-TIM-3 antibody sabatolimab 0:06:51

Anti-TIM-3 antibody sabatolimab + hypomethylating agents for high-risk MDS & AML

Combo proves most 0:01:42

Combo proves most effective in HMA-naive, higher-risk MDS

Therapy-related MDS 0:01:58

Therapy-related MDS

How is higher-risk 0:02:50

How is higher-risk MDS treated?

What Are the 1:02:28

What Are the Current Treatment Options for AML

The current challenges 0:00:59

The current challenges facing high-risk MDS treatment

Rigosertib in combination 0:01:41

Rigosertib in combination with azacitidine: a potential treatment for AML?

MDM2 Inhibitor Shows 0:01:25

MDM2 Inhibitor Shows Promise For Patients With AML

First in-human trial 0:02:59

First in-human trial of AMV564 for AML

Clinical trials investigating 0:01:56

Clinical trials investigating venetoclax combinations for AML

ASH clinical practice 0:03:08

ASH clinical practice guidelines for the treatment of older adults with AML

David Sallman: Magrolimab 0:05:36

David Sallman: Magrolimab Plus Azacitidine Effective in MDS and AML

State of the 0:01:16

State of the art: MDS

Finding the right 0:03:07

Finding the right targets for CAR T-cell therapy in AML

Daniel Pollyea, MD, 0:01:26

Daniel Pollyea, MD, discusses prognostic factors in acute myeloid leukemia (AML) patients

Novel therapies for 0:01:41

Novel therapies for high-risk MDS

Catherine Smith, MD, 0:01:19

Catherine Smith, MD, on whether all acute myeloid leukemia (AML) patients should be tested for FLT3

Future treatment priorities 0:01:21

Future treatment priorities for high-risk MDS